Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Assess PK Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects

NCT06487572 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06487572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06487572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Assess PK Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
July 23, 2024
Completion date
February 7, 2025
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers